Abhijit Bhattacharya: Yeah. Hi, David. Maybe let me answer the first question. I mentioned that there were tough comps on 2021 and 2022. So we had actually a 36% increase in comparable order intake in Diagnosis and Treatment in Q2 2021. And we followed that by another 2% increase last year. So I think that’s where the tough comps come because it’s already on a high order intake number and you see that also in the IR deck, we have shown that on Page 14. The second thing is, of course, we mentioned earlier that it’s lumpy, right? So Q1, we had strong growth. We had a double-digit growth in Q1 And therefore, this lumpiness will continue and that’s why we say also that we have confidence in order intake growth in the second half of the year because the funnel remains strong. The one-off charges, sorry, I missed the second part of the question. The one-off charges is for what? Could you just repeat that, David, your second part of your question?
David Adlington: Yeah. Your guidance on the one-off charges, 100 basis points seems to have shifted from restructuring. That’s gone down by 100 basis points, but your quality related charges with respect to Connected Care has gone up by 100 bps. So just wondered if we should read into that?
Abhijit Bhattacharya: Yeah, no, not really. Basically, as we have been going through the restructuring, we have found that there has been also some attrition so that cost has gone down. And in the second half of the year, we are continuing with the remediation of the 483 that we had. So that is leading to some cost as well as legal cost related to sleep and respiratory. So again, overall the guidance remains the same, but it’s just a shift in line.
David Adlington: Okay. And maybe just a cheeky follow-up. Just into the foreign exchange impact, just on where you’re expecting that to be at current rates for the rest of the year? Thanks.
Abhijit Bhattacharya: Yeah, look, typically, the way we manage our forex, it fluctuates between plus to minus 10 bps to 20 bps in a year. So it should be within that range. It’s not something big that we expect.
David Adlington: Thanks.
Operator: Thank you. We will now go to your next question. And your next question comes from the line of Robert Davies from Morgan Stanley. Please go ahead.
Robert Davies: Yeah. Thanks for taking my questions. My first one was just around the cash guide. I noticed there was no change in the free cash flow guidance for the year even though you had some notable improvement year-on-year and I think in the working capital metrics January to June. And also the CapEx is running lower. So just be kind of interested why you didn’t revise the free cash flow guidance even though the EBIT — sorry, the sales and margin guidance had been updated? That was my first question. My second question was just on trajectory of margins, I guess, in Personal Health. Just be curious what your thought process there going into the back half year. I noticed you are obviously back into positive growth territory, but the margins haven’t really kind of kicked through.
Is there a sort of level we should think about where margins could kick in? And I know there’s quite a seasonal heavy 4Q trajectory there. Just wondered if there’s anything to think about heading into the back half of this year that might change that? And then the last one was just within the D&T business. Obviously, you had a few questions already about order trajectory. Just be curious in terms of modality of product within that business if you’re seeing anything to particularly callout is strong or weak in the quarter? Thank you.
